However, the phase II KEAPSAKE study which evaluated telaglenastat, a glutaminase inhibitor, in advanced non-squamous NSCLC with KEAP1/NRF2 mutations was terminated due to lack of clinical benefits among patients treated with telaglenasta in the interim analysis.212 For PI3K-AKT signaling inhibition, an mTOR kinase inhibitor sapanisertib was evaluated in a phase II clinical trial for advanced or recurrent LSCC with KEAP1/NRF2 mutations (NCT02417701). This evidence concerns the gene PIK3CA and non-small cell lung carcinoma.